US20140004077A1 - Method for treating cervical cancer - Google Patents
Method for treating cervical cancer Download PDFInfo
- Publication number
- US20140004077A1 US20140004077A1 US13/904,209 US201313904209A US2014004077A1 US 20140004077 A1 US20140004077 A1 US 20140004077A1 US 201313904209 A US201313904209 A US 201313904209A US 2014004077 A1 US2014004077 A1 US 2014004077A1
- Authority
- US
- United States
- Prior art keywords
- infected
- hpv
- cervical cancer
- seq
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention fills this need by administering interleukin-20 (IL-20) to a mammalian having cervical cancer.
- IL-20 can also be used to treat a human papillomavirus infection.
- the present invention also provides a method for inhibiting the growth of cervical cancer cells by bringing IL-20 into contact with said cancerous cervical cells.
- Interleukin-20 (formally called Zcyto 10) can be produced according to the method described in International Patent Application No. PCT/US98/25228 filed on Nov. 25 1998.
- the human IL-20 polypeptide is comprised of a sequence of 176 amino acids with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2.
- amino residues 1-24 are signal sequence
- the mature IL-20 polypeptide is represented by the amino acid sequence comprised of residues 25, a leucine, through amino acid residue 176, a glutamic acid residue, also defined by SEQ ID NO:12.
- Another embodiment of the present invention is defined by the sequences of SEQ ID NO: 3 and SEQ ID NO: 4.
- the polypeptide of SEQ ID NO: 4 is comprised of 151 amino acid residues wherein amino acids 1-24 comprise a signal sequence and the mature sequence is comprised of amino acid residues 25, a leucine, through amino acid 151 a glutamic acid, also defined by SEQ ID NO:13.
- Another active variant is comprised of amino acid residues 33, a cysteine, through amino acid residue 176 of SEQ ID NO:2. This variant is also defined by SEQ ID NO:26.
- Mouse IL-20 is also a polypeptide comprised of 176 amino acid residues as defined by SEQ ID NOs: 18 and 19.
- Mouse TL-20 has a signal sequence extending from amino acid residue 1, a methionine, extending to and including amino acid residue 24, a glycine of SEQ ID NO:19.
- the mature mouse IL-20 extends from amino acid residue 25, a leucine, to and including amino acid residue 176 a leucine of SEQ ID NO:19, also defined by SEQ ID NO:20.
- Another active variant is believed to extend from amino acid 33, a cysteine, through amino acid 176, of SEQ ID NO:19. This variant is also defined by SEQ ID NO:25.
- a variant of mouse TL-20 is defined by SEQ ID NOs: 33 and 34.
- This variant is 154 amino acid residues in length and has a signal sequence extending from amino acid residue 1, a methionine, to and including amino acid residue 24, a glycine, of SEQ ID NO:34.
- the mature sequence extends from amino acid residue 25, a leucine, to and including amino acid residue 154, a leucine, of SEQ ID NO:34.
- the mature sequence is also defined by SEQ ID NO:35.
- CIN grades I, II and III correspond to mild, moderate, and severe cervical dysplasia.
- CIN III which includes severe dysplasia and carcinoma in situ, is unlikely to regress spontaneously and, if untreated, may eventually penetrate the basement membrane, becoming invasive carcinoma.
- Squamous cell carcinoma accounts for 80 to 85% of all cervical cancers; adenocarcinomas account for most of the rest.
- Invasive cervical cancer usually spreads by direct extension into surrounding tissues and the vagina or via the lymphatics to the pelvic and para-aortic lymph nodes drained by the cervix. Hematologic spread is possible.
- CIN is usually asymptomatic and discovered because of an abnormal Pap smear.
- Patients with early-stage cervical cancer usually present with irregular vaginal bleeding, which is most often postcoital, but intermenstrual bleeding or menometrorrhagia may occur.
- Patients with larger cervical cancers or advanced-stage disease may present with foul-smelling vaginal discharge, abnormal vaginal bleeding, or pelvic pain.
- Obstructive uropathy, back pain, and leg swelling are manifestations of late-stage disease.
- Suspicious lesions generally first detected by a Pap smear are biopsied. If clinical disease is invasive, staging is performed on the basis of the physical examination, with a metastatic survey including cystoscopy, sigmoidoscopy, IV pyelography, chest x-ray, and skeletal x-rays.
- Cervical cancer can be treated by administration of IL-20 to a female mammal, particularly a human female, afflicted with the disease.
- IL-20 can be administered intralesionally, or intramuscularly for localized disease.
- IL-20 can also be administered by intraperitoneal administration including intravenous administration.
- IL-20 can be administered alone or in conjunction with standard therapies such as surgery, radiation or other chemotherapeutic agents such as bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.
- HPV human papillomavirus
- Genital warts usually appear as soft, moist, minute pink or gray polyps that enlarge, may become pedunculated, and are usually found in clusters. The surfaces resemble the surface of cauliflower. In men they occur most commonly on warm, moist surfaces in the subpreputial area, on the coronal sulcus, within the urethral meatus, and on the penile shaft. In women, the vulva, the vaginal wall, the cervix, and the perineum may become involved. They are particularly common in the perianal region and rectum in homosexual men. Growth rates vary, but pregnancy, immunosuppression, or maceration of the skin may accelerate both the growth of individual lesions and their spread. Genital warts usually can be identified by their appearance but must be differentiated from the flat-topped condyloma lata of secondary syphilis. Biopsies of atypical or persistent warts may be necessary to exclude carcinoma.
- IL-20 can be administered directly into lesions containing cells infected with HPV alone or with standard therapies such as interferon alpha or interferon beta both of which are commercially available.
- Interferon alpha is available from Schering Corporation of Kenilworth, New Jersey and is called INTRON A®.
- Interferon beta is produced by Biogen of Cambridge, MA and is called AVONEX®.
- IL-20 can also be administered with other standard therapies for treating HPV including antimitotics such as podophyllotoxin, podophyllin, or 5-fluorouracil; caustics such as trichloroacetic acid; or interferon inducers such as imiquimod.
- IL-20 for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medications administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in vivo administration of these reagents Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Methods for administration include, intravenous, peritoneal, intramuscular, or intralesional. Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from 1 ⁇ g to 1000 ⁇ g per kilogram of body weight per day.
- the doses may be higher or lower as can be determined by a medical doctor with ordinary skill in the art.
- Excipients and stabilizers can possible be added. These include glycine, histidine, glutamate, aspartate, sugars, sucrose, trehalose, galactose sorbitol, arginine, D-and/or L0amino acids, sugar alcohols, lactose, maltose, threonine, lysine, methionine, isoleucine, a surface active agent such as TWEEN 80, TWEEN 20, polyethylene glycol (PEG) (particularly those PEGs having molecular weights between 1000 and 35000 Da), cetyl alcohol, polyvinylpyrrolidone, polyvinyl alcohol, lanolin alcohol and sorbitan.
- PEG polyethylene glycol
- a reducing agent may be included, such as cysteine, N-acetyl-cysteine, and thioglycerol.
- cysteine such as cysteine, N-acetyl-cysteine, and thioglycerol.
- IL-20 can also me administered in conjunction with other treatments for cervical cancer such as radiation and chemotherapy.
- chemotherapeutic agents include bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.
- Day 2 Dump off media and add a dose response of appropriate ligands in complete growth media (IL-20, zmdal, and MDA7 at 10, 100, and 1000 ng/ml.), along with a positive control retinoic acid (100 uM) in complete growth media, while leaving some wells in complete growth media as controls of how the cells normally grow under normal conditions. Put the cells in incubator and let the assay go for 72 hrs.
- complete growth media IL-20, zmdal, and MDA7 at 10, 100, and 1000 ng/ml.
Abstract
Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus . IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.
Description
- The present application is a divisional of U.S. patent application Ser. No. 10/321,163, filed Dec. 17, 2002, which claims the benefit of U.S. Provisional Patent Application No. 60/341,783, filed on Dec. 17, 2001, both of which are herein incorporated by reference.
- According to the American Cancer Society, 12,800 new cases of invasive cervical cancer would be diagnosed in the United States in 1999. During the same year, 4800 patients were expected to die of the disease. This represents approximately 1.8% of all cancer deaths in women and 18% of gynecological cancer deaths. However, for women aged 20 to 39 years of age, cervical cancer is the second leading cause of cancer deaths. Molecular and epidemiologic studies have demonstrated a strong relationship between human papillomavirus (HPV), cervical intraepithelial neoplasia, (CIN), and invasive carcinoma of the cervix. Thus, there is a need to develop new therapeutic entities for the treatment of human papillomavirus infection, cervical intraepithelial neoplasia and carcinoma of the cervix.
- The present invention fills this need by administering interleukin-20 (IL-20) to a mammalian having cervical cancer. IL-20 can also be used to treat a human papillomavirus infection. The present invention also provides a method for inhibiting the growth of cervical cancer cells by bringing IL-20 into contact with said cancerous cervical cells. Interleukin-20 (formally called Zcyto 10) can be produced according to the method described in International Patent Application No. PCT/US98/25228 filed on Nov. 25 1998. The human IL-20 polypeptide is comprised of a sequence of 176 amino acids with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2. It is believed that amino residues 1-24 are signal sequence, and the mature IL-20 polypeptide is represented by the amino acid sequence comprised of residues 25, a leucine, through amino acid residue 176, a glutamic acid residue, also defined by SEQ ID NO:12. Another embodiment of the present invention is defined by the sequences of SEQ ID NO: 3 and SEQ ID NO: 4. The polypeptide of SEQ ID NO: 4 is comprised of 151 amino acid residues wherein amino acids 1-24 comprise a signal sequence and the mature sequence is comprised of amino acid residues 25, a leucine, through amino acid 151 a glutamic acid, also defined by SEQ ID NO:13. Another active variant is comprised of amino acid residues 33, a cysteine, through amino acid residue 176 of SEQ ID NO:2. This variant is also defined by SEQ ID NO:26.
- Mouse IL-20 is also a polypeptide comprised of 176 amino acid residues as defined by SEQ ID NOs: 18 and 19. Mouse TL-20 has a signal sequence extending from amino acid residue 1, a methionine, extending to and including amino acid residue 24, a glycine of SEQ ID NO:19. Thus, the mature mouse IL-20 extends from amino acid residue 25, a leucine, to and including amino acid residue 176 a leucine of SEQ ID NO:19, also defined by SEQ ID NO:20. Another active variant is believed to extend from amino acid 33, a cysteine, through amino acid 176, of SEQ ID NO:19. This variant is also defined by SEQ ID NO:25.
- A variant of mouse TL-20 is defined by SEQ ID NOs: 33 and 34. This variant is 154 amino acid residues in length and has a signal sequence extending from amino acid residue 1, a methionine, to and including amino acid residue 24, a glycine, of SEQ ID NO:34. Thus, the mature sequence extends from amino acid residue 25, a leucine, to and including amino acid residue 154, a leucine, of SEQ ID NO:34. The mature sequence is also defined by SEQ ID NO:35.
- Cervical dysplasia cells and cervical intraepithelial neoplasia (CIN) cells develop into invasive cervical cancer over a number of years. CIN grades I, II and III correspond to mild, moderate, and severe cervical dysplasia. CIN III, which includes severe dysplasia and carcinoma in situ, is unlikely to regress spontaneously and, if untreated, may eventually penetrate the basement membrane, becoming invasive carcinoma. Squamous cell carcinoma accounts for 80 to 85% of all cervical cancers; adenocarcinomas account for most of the rest. Invasive cervical cancer usually spreads by direct extension into surrounding tissues and the vagina or via the lymphatics to the pelvic and para-aortic lymph nodes drained by the cervix. Hematologic spread is possible.
- CIN is usually asymptomatic and discovered because of an abnormal Pap smear. Patients with early-stage cervical cancer usually present with irregular vaginal bleeding, which is most often postcoital, but intermenstrual bleeding or menometrorrhagia may occur. Patients with larger cervical cancers or advanced-stage disease may present with foul-smelling vaginal discharge, abnormal vaginal bleeding, or pelvic pain. Obstructive uropathy, back pain, and leg swelling are manifestations of late-stage disease. Suspicious lesions, generally first detected by a Pap smear are biopsied. If clinical disease is invasive, staging is performed on the basis of the physical examination, with a metastatic survey including cystoscopy, sigmoidoscopy, IV pyelography, chest x-ray, and skeletal x-rays.
- Cervical cancer can be treated by administration of IL-20 to a female mammal, particularly a human female, afflicted with the disease. IL-20 can be administered intralesionally, or intramuscularly for localized disease. For metastatic disease, IL-20 can also be administered by intraperitoneal administration including intravenous administration. IL-20 can be administered alone or in conjunction with standard therapies such as surgery, radiation or other chemotherapeutic agents such as bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.
- Cells infected with the human papillomavirus (HPV) can be treated with IL-20 to inhibit the proliferation of the virus. Anogenital warts caused by HPV type 6, 11, 16, 18, 31, 33 and 35 are transmitted sexually and have an incubation period of 1 to 6 months. Endocervical wart infections caused by type 16 or 18 have been implicated as a cause of cervical intraepithelial neoplasia and cervical cancer. HPV types 16 and 18 generally do no not cause external genital warts, which are usually caused by types 6 and 11.
- Genital warts usually appear as soft, moist, minute pink or gray polyps that enlarge, may become pedunculated, and are usually found in clusters. The surfaces resemble the surface of cauliflower. In men they occur most commonly on warm, moist surfaces in the subpreputial area, on the coronal sulcus, within the urethral meatus, and on the penile shaft. In women, the vulva, the vaginal wall, the cervix, and the perineum may become involved. They are particularly common in the perianal region and rectum in homosexual men. Growth rates vary, but pregnancy, immunosuppression, or maceration of the skin may accelerate both the growth of individual lesions and their spread. Genital warts usually can be identified by their appearance but must be differentiated from the flat-topped condyloma lata of secondary syphilis. Biopsies of atypical or persistent warts may be necessary to exclude carcinoma.
- IL-20 can be administered directly into lesions containing cells infected with HPV alone or with standard therapies such as interferon alpha or interferon beta both of which are commercially available. Interferon alpha is available from Schering Corporation of Kenilworth, New Jersey and is called INTRON A®. Interferon beta is produced by Biogen of Cambridge, MA and is called AVONEX®. IL-20 can also be administered with other standard therapies for treating HPV including antimitotics such as podophyllotoxin, podophyllin, or 5-fluorouracil; caustics such as trichloroacetic acid; or interferon inducers such as imiquimod.
- The quantities of IL-20 for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medications administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in vivo administration of these reagents Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Methods for administration include, intravenous, peritoneal, intramuscular, or intralesional. Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from 1 μg to 1000 μg per kilogram of body weight per day. However, the doses may be higher or lower as can be determined by a medical doctor with ordinary skill in the art. Excipients and stabilizers can possible be added. These include glycine, histidine, glutamate, aspartate, sugars, sucrose, trehalose, galactose sorbitol, arginine, D-and/or L0amino acids, sugar alcohols, lactose, maltose, threonine, lysine, methionine, isoleucine, a surface active agent such as TWEEN 80, TWEEN 20, polyethylene glycol (PEG) (particularly those PEGs having molecular weights between 1000 and 35000 Da), cetyl alcohol, polyvinylpyrrolidone, polyvinyl alcohol, lanolin alcohol and sorbitan. A reducing agent may be included, such as cysteine, N-acetyl-cysteine, and thioglycerol. For a complete discussion of drug formulations and dosage ranges see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Co., Easton, Pa., 1996), and Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 9th Ed. (Pergamon Press 1996).
- IL-20 can also me administered in conjunction with other treatments for cervical cancer such as radiation and chemotherapy. Examples of chemotherapeutic agents include bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.
- We tested IL-20 in a HeLa299 cytotoxicity assay to measure the ability of IL-20 to prevent cells from growing during normal growth conditions. We used MTT reagent (Promega, Madison, USA) as our detection and readout for this cell inhibition assay . Procedure of a cytoxicity assay:
- Day 1—Plate cells out in complete growth media (with serum) at 5000 cells/well in a 96 well format and let them incubate overnight at 37 degrees and 5% CO2.
- Day 2—Dump off media and add a dose response of appropriate ligands in complete growth media (IL-20, zmdal, and MDA7 at 10, 100, and 1000 ng/ml.), along with a positive control retinoic acid (100 uM) in complete growth media, while leaving some wells in complete growth media as controls of how the cells normally grow under normal conditions. Put the cells in incubator and let the assay go for 72 hrs.
- Day 5—Add 15 ul/well of MTT reagent, let cells inc. for 4 hrs., then add 100 ul of stop solution, let cells inc. for an additional 1 hr., then read the plate on a multilabel counter (Victor2, PerkinElmer Life Sciences Inc., Boston). The MTT protocol will give you two readings, one at a 650 wavelength (background) and one at a 572 wavelength. Subtract the 650 reading from the 572 reading to get your actual output. These numbers are averaged and converted to a % inhibition value.
- Results:
-
- Retnoic Acid gave a 53% inhibition of growth (positive control)
- IL-20 gave a maximal 20% inhibition of growth
Claims (9)
1-7. (canceled)
8. A method of inhibiting the proliferation of a human Papillomavirus (HPV)-infected cell in an individual infected with HPV comprising administering to said individual a therapeutically effective amount of interleukin-20 (IL-20).
9. The method according to claim 8 wherein IL-20 is administered intravenously, peritoneally, intramuscularly or intralesionally.
10. The method according to claim 8 wherein the HPV-infected cell is located within a genital wart or lesion.
11. The method according to claim 10 wherein IL-20 is injected into the infected lesion or infected genital wart of the individual.
12. The method according to claim 11 further comprising electrocauterization, laser, cryotherapy, or surgical excision of at least the genital wart or lesion infected with HPV.
13. The method according to claim 8 wherein IL-20 is a first therapeutic agent that is administered in conjunction with a second therapeutic agent.
14. The method according to claim 13 wherein the second therapeutic agent is selected from the group consisting of interferon alpha, interferon beta, podophyllotoxin, podophyllin, 5-fluorouracil, trichloroacetic acid and imiquimod.
15. The method according to claim 8 wherein IL-20 is administered at a dosage of about 1 μg to about 1000 μg per kilogram body weight per day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/904,209 US20140004077A1 (en) | 2001-12-17 | 2013-05-29 | Method for treating cervical cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34178301P | 2001-12-17 | 2001-12-17 | |
US10/321,163 US7582287B2 (en) | 2001-12-17 | 2002-12-17 | Method for treating cervical cancer |
US12/538,029 US8486382B2 (en) | 2001-12-17 | 2009-08-07 | Method for treating cervical cancer |
US13/904,209 US20140004077A1 (en) | 2001-12-17 | 2013-05-29 | Method for treating cervical cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/538,029 Division US8486382B2 (en) | 2001-12-17 | 2009-08-07 | Method for treating cervical cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140004077A1 true US20140004077A1 (en) | 2014-01-02 |
Family
ID=23339019
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/321,163 Expired - Fee Related US7582287B2 (en) | 2001-12-17 | 2002-12-17 | Method for treating cervical cancer |
US12/538,029 Expired - Fee Related US8486382B2 (en) | 2001-12-17 | 2009-08-07 | Method for treating cervical cancer |
US13/904,209 Abandoned US20140004077A1 (en) | 2001-12-17 | 2013-05-29 | Method for treating cervical cancer |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/321,163 Expired - Fee Related US7582287B2 (en) | 2001-12-17 | 2002-12-17 | Method for treating cervical cancer |
US12/538,029 Expired - Fee Related US8486382B2 (en) | 2001-12-17 | 2009-08-07 | Method for treating cervical cancer |
Country Status (11)
Country | Link |
---|---|
US (3) | US7582287B2 (en) |
EP (2) | EP1977760A3 (en) |
JP (3) | JP4532902B2 (en) |
AT (1) | ATE521361T1 (en) |
AU (1) | AU2002357283B2 (en) |
CA (2) | CA2467723C (en) |
DK (1) | DK1531843T3 (en) |
ES (1) | ES2371006T3 (en) |
IL (1) | IL161978A0 (en) |
PT (1) | PT1531843E (en) |
WO (1) | WO2003051384A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610286B2 (en) * | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
US7122632B2 (en) * | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
US7045498B2 (en) | 2000-08-08 | 2006-05-16 | Zymogenetics, Inc. | Soluble Zcytor11 cytokine receptors |
DE60141546D1 (en) | 2000-09-15 | 2010-04-22 | Zymogenetics Inc | Polypeptides containing the extracellular domain of IL-20RA and / or IL-20RB |
US20040086908A1 (en) | 2002-03-07 | 2004-05-06 | Chandrasekher Yasmin A. | Soluble heterodimeric cytokine receptor |
CA2633171C (en) * | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
JP4532902B2 (en) | 2001-12-17 | 2010-08-25 | ザイモジェネティクス,インコーポレイティド | Treatment method for cervical cancer |
AU2004223836A1 (en) | 2003-03-24 | 2004-10-07 | Zymogenetics, Inc. | Anti-IL-20 antibodies and binding partners and methods of using in inflammation |
WO2005014028A1 (en) * | 2003-08-08 | 2005-02-17 | Novo Nordisk A/S | Interleukin-20 for treating and diagnosing conditions associated with neovascularisation |
WO2005052000A2 (en) | 2003-11-21 | 2005-06-09 | Zymogenetics, Inc. | Anti-il-20 antibodies and binding partners and methods of using in inflammation |
CA2584157C (en) | 2004-10-22 | 2014-10-14 | Zymogenetics, Inc. | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
ATE506063T1 (en) * | 2005-04-27 | 2011-05-15 | Univ Leiden Medical Ct | TREATMENT OF HPV-INDUCED INTRAEPITHELIAL ANOGENITAL NEOPLASIA |
KR20110039218A (en) | 2008-06-30 | 2011-04-15 | 노보 노르디스크 에이/에스 | Anti-human interleukin-20 antibodies |
US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
JP2013520476A (en) | 2010-02-26 | 2013-06-06 | ノヴォ ノルディスク アー/エス | Stable antibody-containing composition |
US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
MX339762B (en) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Immunomodulator metallopeptides (immps) and compositions containing same. |
WO2014015133A1 (en) | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
MX2019001389A (en) | 2019-01-31 | 2020-02-20 | Atso Corp Affairs S A De C V | Anti-sense oligonucleotides of glutathione s transferase for cancer treatment. |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5436155A (en) | 1991-12-31 | 1995-07-25 | Arch Development Corporation | Isolated DNA encoding a somatostatin receptor |
US5789192A (en) | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
JP2001500369A (en) | 1996-08-30 | 2001-01-16 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | Interleukin-19 |
US5985614A (en) | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
CA2288992C (en) | 1997-04-30 | 2012-06-12 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
CA2296762A1 (en) | 1997-07-16 | 1999-01-28 | Human Genome Sciences, Inc. | Interleukin-20 |
US6486301B1 (en) | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
US5965704A (en) | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
CA2298439A1 (en) | 1997-08-06 | 1999-02-18 | Zymogenetics, Inc. | Lipocalin homologs |
HU227703B1 (en) | 1997-11-26 | 2011-12-28 | Zymogenetics Inc | Mammalian cytokine-like polypeptide-10 |
US6576743B1 (en) | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
ES2226335T3 (en) | 1998-01-23 | 2005-03-16 | Immunex Corporation | RECEOOCTIRES OF UK.18. |
AU2871899A (en) | 1998-03-09 | 1999-09-27 | Schering Corporation | Human receptor proteins; related reagents and methods |
ES2312205T3 (en) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | NEW POLYPEPTIDE AND NUCLEIC ACIDS THAT CODE IT. |
US6982320B2 (en) | 1998-03-19 | 2006-01-03 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
AU5203199A (en) | 1998-05-26 | 1999-12-13 | Procter & Gamble Company, The | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
AU6144499A (en) * | 1998-09-15 | 2000-04-03 | University Of Pittsburgh | In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression |
WO2000039161A1 (en) | 1998-12-31 | 2000-07-06 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
WO2000073457A1 (en) | 1999-05-27 | 2000-12-07 | Schering-Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
AU2883700A (en) | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
EP2248828A1 (en) | 1999-12-23 | 2010-11-10 | ZymoGenetics, Inc. | Method for treating inflammation |
US7045498B2 (en) | 2000-08-08 | 2006-05-16 | Zymogenetics, Inc. | Soluble Zcytor11 cytokine receptors |
WO2002058724A2 (en) | 2001-01-26 | 2002-08-01 | Eli Lilly And Company | Use of lp82 to treat body weight disorders |
CN1503677A (en) | 2001-02-28 | 2004-06-09 | Use of LP 82 to treat hematopoietic disorders | |
CA2440596C (en) | 2001-03-09 | 2011-05-24 | Zymogenetics, Inc. | Soluble heterodimeric cytokine receptor |
DE10154579A1 (en) | 2001-11-07 | 2003-05-28 | Medigene Ag | Topical use of cytokines and chemokines for the treatment of viral or mycotic skin diseases or tumors |
JP4532902B2 (en) | 2001-12-17 | 2010-08-25 | ザイモジェネティクス,インコーポレイティド | Treatment method for cervical cancer |
AU2004223836A1 (en) | 2003-03-24 | 2004-10-07 | Zymogenetics, Inc. | Anti-IL-20 antibodies and binding partners and methods of using in inflammation |
-
2002
- 2002-12-17 JP JP2003552317A patent/JP4532902B2/en not_active Expired - Fee Related
- 2002-12-17 EP EP08159216A patent/EP1977760A3/en not_active Withdrawn
- 2002-12-17 CA CA2467723A patent/CA2467723C/en not_active Expired - Fee Related
- 2002-12-17 US US10/321,163 patent/US7582287B2/en not_active Expired - Fee Related
- 2002-12-17 WO PCT/US2002/040309 patent/WO2003051384A1/en active Application Filing
- 2002-12-17 PT PT02805181T patent/PT1531843E/en unknown
- 2002-12-17 IL IL16197802A patent/IL161978A0/en unknown
- 2002-12-17 AT AT02805181T patent/ATE521361T1/en active
- 2002-12-17 EP EP02805181A patent/EP1531843B1/en not_active Expired - Lifetime
- 2002-12-17 CA CA2746308A patent/CA2746308A1/en not_active Abandoned
- 2002-12-17 AU AU2002357283A patent/AU2002357283B2/en not_active Ceased
- 2002-12-17 DK DK02805181.1T patent/DK1531843T3/en active
- 2002-12-17 ES ES02805181T patent/ES2371006T3/en not_active Expired - Lifetime
-
2009
- 2009-08-07 US US12/538,029 patent/US8486382B2/en not_active Expired - Fee Related
- 2009-09-04 JP JP2009204182A patent/JP2010013467A/en not_active Withdrawn
-
2012
- 2012-11-30 JP JP2012261834A patent/JP2013049713A/en active Pending
-
2013
- 2013-05-29 US US13/904,209 patent/US20140004077A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4) * |
Hsieh et al. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes and Immunity (2006) 7, 234-242. * |
Hsu et al. Anti-IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth. Mol Cancer Res; 10(11) November 2012, p1430-1439. * |
Hsu et al. The Therapeutic Potential of Anti-Interleukin-20 Monoclonal Antibody. Cell Transplantation, Vol. 23, pp. 631-639, 2014. * |
Li et al. Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure. Genes and Immunity (2008) 9, 395-404. * |
Also Published As
Publication number | Publication date |
---|---|
CA2746308A1 (en) | 2003-06-26 |
US8486382B2 (en) | 2013-07-16 |
EP1531843B1 (en) | 2011-08-24 |
PT1531843E (en) | 2011-10-27 |
ES2371006T3 (en) | 2011-12-26 |
AU2002357283B2 (en) | 2007-08-16 |
US20030161811A1 (en) | 2003-08-28 |
JP2013049713A (en) | 2013-03-14 |
EP1531843A4 (en) | 2007-02-14 |
JP4532902B2 (en) | 2010-08-25 |
CA2467723C (en) | 2011-09-27 |
DK1531843T3 (en) | 2011-12-12 |
US20090311215A1 (en) | 2009-12-17 |
EP1531843A1 (en) | 2005-05-25 |
IL161978A0 (en) | 2005-11-20 |
EP1977760A3 (en) | 2009-11-04 |
CA2467723A1 (en) | 2003-06-26 |
ATE521361T1 (en) | 2011-09-15 |
US7582287B2 (en) | 2009-09-01 |
WO2003051384A1 (en) | 2003-06-26 |
JP2010013467A (en) | 2010-01-21 |
JP2005524608A (en) | 2005-08-18 |
AU2002357283A1 (en) | 2003-06-30 |
EP1977760A2 (en) | 2008-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8486382B2 (en) | Method for treating cervical cancer | |
JP2005524608A5 (en) | ||
Beutner et al. | Genital warts and their treatment | |
Gollnick et al. | Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day | |
Gross et al. | Systemic treatment of condylomata acuminata with recombinant interferon-alpha-2a: low-dose superior to the high-dose regimen | |
Schneider et al. | Interferon treatment of human genital papillomavirus infection: importance of viral type | |
Reinhard et al. | Successful treatment of ulcerated necrobiosis lipoidica with mycophenolate mofetil | |
Crowther et al. | Verrucous carcinoma of the female genital tract: a review | |
McGregor et al. | Necrobiotic xanthogranuloma without periorbital lesions | |
Koonsaeng et al. | Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir | |
Dinsmore et al. | Recombinant human interferon-in the treatment of condylomata acuminata | |
Zachariae et al. | Recombinant interferon alpha-2a (Roferon-A) in a case of Buschke-Löwenstein giant condyloma | |
Savoca et al. | CO 2 laser vaporization as primary therapy for human papillomavirus lesions: A prospective observational study | |
Sonnex et al. | The treatment of human papillomavirus lesions of the lower genital tract | |
EP1383512A1 (en) | Use of sucralfate for the treatment of cervical erosion | |
Foldvari et al. | Clinical observations with topical liposome-encapsulated interferon alpha for the treatment of genital papillomavirus infections | |
Cardamakis et al. | Treatment of urethral condylomata acuminata or flat condylomata with interferon-α2a | |
Monsonego et al. | Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum. | |
Bornstein et al. | Treatment of a patient with vulvar vestibulitis by intramuscular interferon β; a case report | |
Schneider et al. | Efficacy trial of topically administered interferon gamma-1β gel in comparison to laser treatment in cervical intraepithelial neoplasia | |
Pellicano et al. | Multiple keratoacanthomas and junctional epidermolysis bullosa: a therapeutic conundrum | |
Lebwohl et al. | Interferon and condylomata acuminata. | |
De Palo et al. | The Role of Beta Interferon in the Treatment of Cervical Dysplasia | |
Choi et al. | Herpetic infection on the vulva associated with eccrine squamous syringometaplasia in malignant lymphoma | |
Kenney et al. | Human papillomavirus as expressed in cervical neoplasia: evolving diagnostic and treatment modalities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |